Anticoagulation medications are frequently used for primary and secondary treatment of several thrombo-embolic disorders. An important side effect of all anticoagulants is hemorrhagic diathesis which necessitates acute treatment, ideally using medicinal therapy with an antidote. Much experience has been gained in treating bleeding while on traditional anticoagulants, such as heparins and vitamin K antagonists by the use of antagonists. A multitude of factor-specific anticoagulants have recently been introduced or will soon receive approval. With this new generation of anticoagulants no valid laboratory parameters or effective antagonists are presently available. Due to a lack of adequate studies regarding acute treatment this can at present only be carried out on a symptomatic basis.
|Translated title of the contribution
|Old and new anticoagulants: Antidotes and measures for acute hemorrhaging and urgent interventions
|Number of pages
|Published - Jan 2010
- Acute hemorrhage
- Clinical treatment
- Drug monitoring
Dawa za kuzuia kuganda kwa damu hutumiwa mara nyingi kwa ajili ya matibabu ya msingi na ya sekondari ya magonjwa kadhaa ya thrombo-embolic. Athari muhimu ya anticoagulants ni hemorrhagic diathesis ambayo inahitaji matibabu ya haraka, bora kutumia tiba ya dawa na antidote. Matibabu ya upungufu wa damu kwa kutumia dawa za kawaida za kuzuia kuganda kwa damu kama vile heparin na vitamini K ni muhimu. Vifaa vingi vya kuzuia kuganda kwa damu vilivyo na viungo fulani vimetolewa hivi karibuni au vitatolewa hivi karibuni. Kwa kizazi hiki kipya cha anticoagulants hakuna vigezo halali vya maabara au antagonists ufanisi zinapatikana kwa sasa. Kwa sababu ya ukosefu wa masomo ya kutosha kuhusu matibabu ya kali hii kwa sasa inaweza tu kufanyika juu ya msingi wa dalili. "Kama ilivyoelezwa katika makala ya ""Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-